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RON - The Con in Colorectal Carcinoma
Shikha Tarang and Jing Wang*
Eppley Institute for Research in Cancer and Allied Diseases University of Nebraska Medical Center, Omaha NE, USA
Abstract: The recepteur d’origine nantais (RON) is a member of MET family of receptor tyrosine kinase (RTKs), an
overexpression of which has been observed in several cancers. The expression of RON gene is required during embryonic
development and also plays critical roles in regulating macrophage inflammatory response. In CRC, the overexpression of
moderate RON activity contributes to their oncogenic potential by regulating several key processes such as proliferation,
motility and resistance to apoptosis. Interestingly, an aberrant RON expression is often associated with the generation of
several splice variants with unique transforming activities. The targeting of RON signaling pathway by the use of monoclonal antibodies and small-molecule inhibitors has shown promising therapeutic results in animal models. The present article aims at summarizing the current understanding of RON kinase in CRC.
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INTRODUCTION
Receptor Tyrosine Kinases (RTKs) are cell-surface receptors for several growth factors, cytokines and hormones
[1]. Signaling by RTKs is one of the major mechanisms of
intracellular communication during embryonic development
and physiological processes. However during pathological
conditions such as cancer either inappropriate activation or
disruptions of regulatory mechanisms lead to constitutively
activated pathways [2, 3]. RON belongs to MET protooncogene family and shares significant structural and functional homology with cMET [4]. There is also a high degree
of homology between MSP (Macrophage stimulating protein, the ligand for RON) and HGF/SF (Hepatocyte-growth
factor/Scatter factor, the ligand for RON) [5].
RON gene is embryonic lethal in pre-implantation stage
suggesting its critical role in embryonic development [6]. In
adults a moderate RON gene expression is observed in several epithelial tissues and macrophages [5, 7]. The activation
of RON by serum-protein MSP under physiological conditions becomes leaky in cancer consequent to several chromosomal aberrations which lead to a ligand-independent activation of RON [8]. Thus an aberrant overexpression of RON is
observed in many cancers such as colon, breast and pancreatic cancers [9-13]. RON overexpression has been shown
important in driving tumorigenesis and is associated with
poor prognosis. Interestingly overexpression of RON is often
associated with the generation of splice variants each with a
unique expression profile and characteristic structural and
functional properties [14-16].
Colorectal cancer (CRC) is the third most common cancer and second leading cause of cancer related deaths in the
United States [17-19]. Although a number of screening
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methods have been developed, their effectiveness is limited
due to lack of awareness and financial constraints [19, 20].
Metastasis largely determines the survival time of patients
and accounts for the majority of CRC deaths [21]. Upon metastasis surgical resection is limited while radiation and chemotherapy are only palliative. A molecular understanding of
the phenomenon is thus urgently warranted to prolong the
survival time of CRC patients with distant metastasis.
Previous studies have demonstrated the aberrant RON
expression in majority of CRC patients [10, 22, 23]. Studies
from our own laboratory and others have shown that RON
contributes to the malignant and invasive phenotype of CRC
[24]. RON has been shown to regulate several key processes
in colon tumor progression and also plays active role in EMT
which is analogous its role in embryonic development [25].
The function of RON in EMT is of particular clinical interest
as the transition from epithelial to mesenchymal phenotype
is a major determinant of metastatic dissemination [26]. Thus
targeting RON is expected to have significant therapeutic
efficacy in limiting the spread of metastatic CRC. Several
RTK inhibitors have proven their success clinically in the
past further encouraging the studies on the therapeutic utilization of RON RTK [1, 27, 28]. The characteristics of RON
such as high prevalence in CRC and cell-surface RTK activity make it an important candidate for anti-cancer therapies.
Further studies are warranted to develop and test the utility
of targeting RON signaling in CRC. The article summarizes
our present understanding on RON in pathogenesis of CRC.
THE BIOLOGY OF RON
The cloning of human RON cDNA was done less than
two decades ago in 1993 from the library of human keratinocytes [29]. The frequently altered RON gene in cancers is
16.8 kb and located on chromosome 3p21 [29]. The mature
RON receptor is 180 kDa protein with 40 kDa extracellular
Į- chain and 150 kDa ȕ- chain with extracellular, transmembrane and cytoplasmic domains and intrinsic kinase activity
[5, 30]. The two Į- and ȕ- chains are linked by a disulphide
2012 Bentham Open
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bond. The extracellular domain of RON consists of well defined sema (N-terminal semaphoring), PSI (plexin semaphore-and integrin) and four immunoglobulin-like IPT domains. The only identified ligand for RON receptor is MSP
(macrophage stimulating protein) [31]. The gene for MSP is
located at a similar position as RON on chromosome 3p21
[32]. MSP is synthesized by hepatocytes and circulates in
blood as inactive precursor pro-MSP [33]. The mature heterodimeric MSP consisting of a 60 kDa Į-chain and 30 kDa
ȕ-chain is generated by proteolytic cleavage at dibasic arginine–valine (R554–V555). The receptor-binding site of MSP is
located in the MSP ȕ-chain. The Į-chain contains four triple
disulfide loop structures called kringle domains. The ȕ-chain
contains a serine protease-like domain in which there is substitution of three amino acids making it devoid of any enzymatic activities [34].
The expression of RON gene is observed early in the
embryonic development. In mice homozygous loss of RON
gene (Ron-/-) leads to death prior to ED (embryonic day) 6.5
suggesting that RON is critical in embryonic development
[6]. In adult tissues the expression of RON gene in epithelial
cells enhances their adhesion and motility. For instance
RON-MSP signaling increases the ciliary beat of nasal mucosal cells [35] and plays role in sperm motility in epithelium of the epididymis [36]. In tissue macrophages RON
regulates the extent of their activation and inflammatory response [7].
RON SPLICE VARIANTS
An interesting and unique phenomenon in RON mediated
tumorigenesis is the existence of splice variants. Intriguingly
wild-type (wt) RON does not have cellular transforming activities on ectopic expression in NIH3T3 cells while several
other variants isolated and cloned from tumor samples induce tumorigenic properties upon transformation [14, 37]. In
CRC in addition to the overexpression of wt RON there is
also existence of splice variants in certain tumor tissues. The
three splice variants that have been detected are namely
RONǻ165, RONǻ160, and RONǻ155 the expression and
occurrence of which has been confirmed by the use of antiTable 1.

bodies targeting different regions of RON [10, 23]. The
splice variants have been shown to play important roles in
the progression of CRC in vivo. For instance RONǻ160 and
RONǻ155 when transfected in NIH3T3 cells have the ability
to induce focus formation and anchorage independent
growth. Further NIH3T3 cells expressing RONǻ160 or
RONǻ155 form tumors in athymic nude mice and show distant metastasis to lungs [10]. The variant RONǻ160 was
initially discovered in HT29 colon cancer cells [16] and later
confirmed in tumor samples from CRC patients. These three
RON splice variants are generated by deletions in extracellular ȕ-domain leading to the abnormal dimerization. A comparative analysis of the different variants of RON and their
oncogenic potential has been done in Table 1. Interestingly
RON mutants maintain a high level of expression in CRC by
resisting the process of receptor endocytosis and ubiquitylation which is observed in wt RON [38, 39].
Recently a naturally occurring antagonist of RON
(RONǻ85) was identified in CRC and other cancers.
RONǻ85 is the soluble form of RON which act by competing with wt RON for MSP binding and signaling. It is generated with an insertion of 49 nucleotides between exons 5 and
6 which introduces a premature stop codon leading to the
formation of a truncated 85 kDa RON variant consisting of
entire 35 kDa Į-chain and a 45 kDa partial extracellular ȕchain. The protein comprises a sema domain, hinge motif
and portion of the first IPT unit. Interestingly the variant
RONǻ85 was not translated in cancer cells but demonstrated
an inhibitory activity when used as a recombinant protein.
RONǻ85 inhibits ERK1/2 and AKT phosphorylation and
tumorigenic properties of CRC cells [40]. The study underscores the complexity in regulation of RON translation in
cancer cells and suggests an alternative approach for RON
targeted therapy.
The investigation whether a mutation in the RON kinase
domain contributes to the constitutive activity in colon cancer cells was done in a panel of five carcinoma cell lines HT29, DLD-1, HCT116, SW620 and SW837. There were no
mutations found but a single-nucleotide polymorphism
(A4031G) in HT29 and SW620 cells [9]. Though the pres-
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ence of mutations has not been investigated in the tumor
tissues from CRC patients these initial findings indicate that
receptor overexpression leading to dimerization and activation is the major mechanism of RON activity in CRC.
In order to decipher the molecular mechanisms of cancer
specific RON aberrant splicing, the role of SF2/ASF splicing
factor was investigated [41]. SF2/ASF on binding to the
regulatory ‘control cassettes’ in Exon12 promotes inclusion
of Exon11. Thus by regulating the ratio of wt RON and
RONǻ165 transcripts SF2/ASF regulates the tumorigenic
potential of the colon cancer cells. Overexpression and
knockdown studies on SF2/ASF exhibited a phenotype
which is similar to that of RONǻ165 further emphasizing the
role of SF2/ASF in regulating its splicing [41]. In another
study the role of first IPT domain in regulating the tumorigenic potential of RON was investigated in RONǻ160 and
RONE5/6in which are generated by 109 amino acid deletion
and 20 amino acid insertion respectively between Exon5 and
Exon6 [42]. It was observed that the two variants are quite
different functionally - though RONǻ160 showed constitutively active signaling, the activation of RONE5/6in required
stimulation with ligand MSP. Further RONǻ160 showed
higher tumorigenic potential and resistance to antibody mediated receptor internalization as compared to RONE5/6in[42].
These findings therefore underscore the importance of IPT
units in RON signaling. Further studies need to be done to
comprehend fully the mechanisms of splice variants generation and a post-transcriptional regulation which translate to
abnormal proteins thereby contributing to the malignant phenotype.
ONCOGENIC POTENTIAL OF RON
RON regulates several key processes in tumor development such as proliferation, motility and invasion [22, 23].
Several cancers of epithelial origin show a marked elevation
in RON expression contributing to their malignant phenotype
[43]. RON overexpression has high prevalence in CRC
where majority of tumor tissues and cell lines from primary
and metastatic CRC are shown to be positive for RON expression [43]. It is noteworthy that the inflammatory conditions such as colitis which are positively correlated with risk
of CRC also show high RON expression [44].
RON was found to be over expressed and constitutively
active in colon cancer cells as compared to the normal
epithelial cells or SV40 transformed cells indicating the role
of RON in malignant phenotype of CRC cells [9]. To elucidate whether abnormal RON activation is associated with
tumorigenic properties in these cells ectopic expression of
RON was carried out in SV40 transformed CoTr and colon
cancer cells. It was observed that RON overexpression not
only increases the migratory and invasive potential in these
cells but also protects them from apoptotic stimuli [9]. The
study demonstrates the biological implications of RON overexpression in pathogenesis of CRC.
The differential expression of RON in in vitro studies
was corroborated by immunohistochemical (IHC) staining of
the tumor tissues obtained from CRC patients [10]. In addition to the significantly higher RON staining intensity the
tumor cells also showed a characteristically distinct pattern
of staining as compared to the normal colon. In mucosal cells
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from the normal colon a granular expression of RON is observed on the cell surface and cytoplasm whereas in cancerous cells RON expression is diffused throughout the cytoplasm. The significance of the changes in expression pattern
is not understood but may be indicative of their contribution
to the progression of CRC [10]. An investigation into distinct
staining patterns between normal and cancerous tissues
might provide important clues on RON sub-cellular localization in physiological and pathological conditions. However it
should be pointed here that a previous study which used another antibody for staining RON failed to identify any overexpression of RON protein in CRC [45].
In another study a comprehensive transcriptional profiling of RON and other kinases was done in different CRC
stages - normal colon mucosa, adenomatous polyps, primary
carcinoma and secondary metastases [46]. Though the study
demonstrated a positive and differential RON expression in
tumors derived from primary CRC patients it failed to detect
any changes in the RON transcript in secondary colon metastasis using RT-PCR based approach [46]. Previous studies
have emphasized RON is implicated in metastatic phenotype
of CRC. The discrepancy in the study may be attributed to
the limitation in the use of RT-PCR based approach of quantification which may not represent the actual difference in
the expression pattern.
Activated RON signaling regulates the characteristic
hallmarks of malignancy such as cell spreading, dissociation,
migration and invasive potential [22, 47, 48] The metastatic
dissemination of epithelial cancers is often accompanied by
the phenomenon of EMT which encompasses loss of epithelial properties and acquisition of mesenchymal phenotype
[26]. Thus one of the main mechanisms by which RON facilitates tumor progression is by playing instrumental role in
the process of EMT. RON mediated effects are manifested
by associated morphological changes and in vitro assays.
The biological functions of RON kinase were studied using
the gene inactivation and overexpression strategies. When
normal colonic cells AA/C1 were over expressed with RON
they exhibited transforming phenotype of colony formation
and increase in motility [49]. Similarly inactivation of RON
gene significantly affected the classical tumorigenic properties of cell proliferation, migration and tumor growth in animal models of colon cancer [10, 49]. These studies demonstrate that RON is critical in regulating the malignant properties of colorectal cancer. A positive RON expression in several patient tissues further emphasizes the role of RON
kinase in regulating tumorigenic potential in CRC. Therefore
to investigate whether RON has a role in early stage tumorigenesis, ApcMin/+ mouse was generated with and without
RON signaling (ApcMin/+ RON+/+ and ApcMin/+ RON-/-) [50].
ApcMin/+ mouse is a well studied mouse model in CRC and
carries a truncation mutation at codon 850 of the Apc gene
and forms multiple colon tumors. The findings from these
studies show that in the presence of Apc mutation RON is
not required for the development and progression of CRC in
mice.
RON ACTIVATED SIGNALING PATHWAYS
In physiological conditions the binding of RON with its
ligand MSP causes tyrosine phosphorylation and consequent
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homo-dimerization and activation of the RON receptor.
However in CRC RON receptor overexpression or generation of alternate RON splice variants lead to the ligandindependent mechanisms for RON activation [8, 51]. It is
suggested that pre-formed RON homodimers may also be
activated as the result of cell interaction with the ECM [52].
The molecular mechanisms of transducing signals in the absence or presence of ligand may however be strikingly different. Notably aberrant RON activity also alters the tyrosine-phosphorylation of several proteins which may be another mechanism of RON induced cellular transformation.
The activation of RON RTK regulates a number of signaling
pathways such as PI3K-AKT, Ras, Src, FAK and ȕ-Catenin
which in turn regulate several key processes of malignant
transformation thereby amplifying the tumorigenic potential
of cells harbouring RON overexpression [53]. The role of
RON was investigated in relation to deregulated mutant
PI3K signaling pathway in CRC. Mutations in PIK3CA
which encodes the p110Į catalytic subunit of PI3K are observed in a large number of CRC patients and HCT116
which has H1076R gain of function mutation. It was observed that knockdown of RON kinases inhibits the activation of mutant PI3K and thereby the metastatic potential of
orthotropically injected colon cancer cells [24]. RON siRNA
inhibited signaling by ȕ-catenin suggesting the regulation of
this pathway by RON kinase [49, 50]. However, the effect of
RON in ȕ-catenin expression and signaling was not observed
in ApcMin/+ mice. The association of RON with ȕ-catenin and
PI3K signaling is highly significant with regards to pathogenesis of CRC - while ȕ-catenin is essential for initiating
the tumor formation in colon PI3K is important for cell sur-

vival and also the metastatic spread and invasion at later
stages of CRC progression [54-56]. Thus targeting RON
RTK signaling may have profound implications in blocking
several downstream and cross-activated signaling pathways
Fig. (1) illustrates the RON activated signaling pathways in
CRC progression.
THERAPEUTIC TARGETING OF RON KINASE
Several cancers show aberrant RTKs signaling which are
the primary transducers of extracellular growth factor signals
into the cell. The significance of targeting RTK signaling has
been successfully demonstrated with a large number of FDA
approved drugs in clinics [1,28]. In CRC monoclonal antibodies targeting RTKs are against VEGF (Bevacizumab) and
EGFR (Cituximab and Panitumumab) [57]. An aberrant signaling from RON RTK is observed in majority of CRC patients and therefore targeting RON holds promise in achieving appropriate therapeutic outcomes. The cell-surface RON
has the potential as a direct drug target or as the delivery
molecule in combination with chemotherapeutic agents. The
prospect of clinically targeting RON is currently being explored by the two main strategies - the development of neutralizing monoclonal antibodies and use of small molecule
kinase inhibitors. The monoclonal antibodies (mAb) used to
study the effect of blocking RON signaling pathways in
CRC include Zt/f2, Zt/g4, Zt/c9 and Zt/c1 and act by inducing receptor internalization followed by protein degradation
[58-60]. Zt/g4 and Zt/c9 both recognize epitopes on the sema
sequence while Zt/f2 binds with epitopes on the IPT domain.
It was observed that these mAb show a synergistic effect
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wherein a combination of any two mAbs shows a synergistic
response with concomitant higher RON internalization and
degradation. Further treatment with neutralizing mAbs in
addition to down regulating RON-ȕ chain expression also
inhibits the expression of pro-RON. It was observed that
treatment with Zt/f2 causes tumor regression in as early as
five days of administration in xenograft mouse model [60].
An in vitro assay shows that although the antibody induces
the phosphorylation of RON receptor initially it subsequently
leads to receptor internalization and thus favourable biological outcomes. Further Zt/f2 potentiates the effect of chemotherapeutic drug 5-florouracil. The tumor growth inhibitory
effect is observed in both immune competent BALB/c mice
and athymic nude mice deficient in T-cell mediated immunity. Treatment with mAb Zt/g4 was shown to affect the
ability of colon cancer cells for colony formation in soft agar
and increase the chemo-sensitivity of SW620 cells in response to gemcitabine treatment [58]. The therapeutic efficacy of blocking RON with monoclonal antibodies has also
been tested in combination with other chemotherapeutic
drugs. Zt/g4 and Zt/c1 were tested for their ability to be used
as a drug carrier by coating them with immunoliposome
(ILP) and loading with cytotoxic drug doxorubicin (Dox)
[59, 61]. It was observed that both Anti-RON Zt/g4 and
Zt/c1 antibodies were highly effective in selectively killing
colon cancer cells than pegylated liposome doxorubicin.
Further the anti-tumorigenic activities of anti-RONDOX-IL were evaluated in hypoxic cancer cells HCT116
and SW620 cells [61]. It is believed that the hypoxic conditions of the tumor microenvironment induce a drug resistance phenotype to the cancer cells [62]. Therefore the therapeutic utility of anti-RON-DOX-IL conjugate was evaluated
under hypoxic conditions. It was observed that anti-RONDOX-IL treated HCT116 and SW620 cells have reduced
IC50 over administration of DOX or DOX-IL. These effects
were found to be dependent on hypoxic RON expression
further strengthening the utility of targeting RON signaling
pathway in CRC. Another RON binding antibody
IMC41A10 developed by ImClone Systems has been shown
to block the interaction between RON and its ligand MSP
with a high affinity [63]. The efficacy of RON kinase has
been demonstrated in several cancers including HT29 colon
cancer cells wherein IMC41A10 has been shown to inhibit
MSP induced phosphorylation and downstream signaling
events. IMC41A10 is also shown to inhibit the HCA7 colon
cell migration in response to MSP. Further the anti-tumor
activity of IMC41A10 was shown in xenograft mouse model
of HT-29 wherein it showed 50-60% inhibition in tumor
growth as a single agent [63]. Anti-RON directed receptor
internalization represents an analogous situation where cells
control the level of responsiveness to extracellular signals by
inducing endocytosis of the receptor. Consequently therapeutic exploitation of this natural feedback mechanism to deliver
cytotoxic drugs represents a promising novel approach combining inactivation of RON signaling with tumor cell killing
thereby increasing the effectiveness of the therapy. The use
of mAb in therapeutic targeting of RON suffers limitation in
case of tumors where RON is activated in a ligandindependent manner as antibody presumably acts by blocking the interaction between RON and MSP [63]. Moreover
certain variants of RON are present in the cytoplasm and
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consequently not amenable to antibody directed therapies.
Therefore a small-molecule kinase inhibitor is expected to
have broader application in RON-driven CRC. The small
molecule inhibitors described so far for RON also inhibit
closely related c-Met kinase. Several SMI such as quinoline
based compound from Amgen, BMS-777607 from BristolMyers Squib and compound I have been described to inhibit
RON/cMet kinase [64]. Compound I has been shown to result in partial inhibition of HT-29 colon xenografts [65].
However the high sequence similarity between the catalytic
domains of these kinases makes the design of specific inhibitors challenging [5].
RON IN TUMOR MICROENVIRONMENT
Several studies have demonstrated that aberrant RON
activity on tumor cells leads to their increased tumorigenic
potential. However the role of RON in tumor microenvironment remains largely unknown. Though RON regulates the
extent of activation in several populations of tissue macrophages whether it has significance in the tumor-associated
macrophages (TAMs) is not well understood. The classical
theory of macrophage activation proposes the existence of
alternative M1 and M2 states of macrophage activation
where M2 regulates the extent of inflammatory response by
M1 [66, 67]. In tissue macrophages RON activation is associated with inhibiting Th-1 mediated inflammatory response
to injury and inflammation. RON signaling suppresses several hallmarks of M1 polarized macrophages such as iNOS,
TNF-Į and IL-12. As RON plays active role in attenuating
the inflammatory response its expression associated with M2
macrophage sub-population [68].
Tumor microenvironment is largely infiltrated by a distinct macrophages population known as tumor-associated
macrophages (TAMs) which play significant roles in shaping
the developing tumor. TAMs participate in carcinogenesis by
facilitating and maintaining an immuno- suppressive state
wherein the extent of infiltration by TAMs is positively correlated with poor prognosis in many cancers including CRC.
An important metabolic switch in M1 and M2 polarization is
Arg1 (arginase1) which is also associated with suppression
of immune response and a tumor promoting phenotype. Recently it was shown TAMs isolated from RON -/- mice show
higher expression of Arg1 [68]. Further studies are warranted
to decipher whether RON plays a similar role in TAMs from
the CRC. If the immunosuppressive role of RON in TAMs
holds true in CRC it would further strengthen the efficacy of
RON targeted anti-cancer therapies.
FUTURE DIRECTIONS
The role of aberrant RON RTK signaling in pathogenesis
of CRC has been established with previous studies. The existence of several RON splice variants in CRC makes it a particularly interesting molecule and needs further exploration.
Though the occurrence of splice variants have been reported
in CRC the functional implications of their expression in
only a small subset of tumor samples remain enigmatic.
Though RON signaling drives several key processes of neoplastic transformation whether colon cancer cells are addicted to RON activation is presently not known. Several
kinase inhibitors such as imatinib and geftinib have been
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very successful in the clinics due to the phenomenon of oncogene addiction. Recently it is shown that cross-talk between RON and MET sustains the oncogene addiction of
MET [69]. Thus study of the phenomenon of oncogene addiction with reference to RON activation in colon cancer will
further strengthen the avenues for therapeutic utilization of
RON RTK. In addition to the targeting of RON kinase in
cancer cells, an investigation into the biological role of RON
in TAMs would be highly desirable as non-malignant cells
are less likely to evolve to a drug resistant phenotype.
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